

Cell Line Data Sheet for CHLA-9

Disease: Primitive neuroectodermal tumor (PNET)
Phase of Therapy: Diagnosis
Treatment: None
Disease Stage:
Gender: Female
Age at diagnosis: 14 years
Race: N/A
Age at sample collection: N/A
Source of Culture: Solid tumor (thoracic mass)
Primary Tumor Site: Thorax
Date Established: 1987

EWS/FLI1 Status: FLI1
p53 functionality: Functional
Karyotype:
Modal No:

R-IC50 (DIMSCAN*):	<u>Vincristine (ng/ml)</u>	<u>Melphalan (µg/ml)</u>	<u>Etoposide (ng/ml)</u>	<u>Rapamycin (ng/ml)</u>
*see reference 1	0.51 ± 0.06	0.14 ± 0.06	0.1 ± 0.00	0.85 ± 0.19

Growth Conditions: Please see Protocols section at <https://www.cccells.org/protocols.php>
5% CO₂, 20% O₂, 37.0°C

Media Formulation: Please see Protocols section at <https://www.cccells.org/protocols.php>
Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)

Doubling Time: 51 hours
Growth Properties: Teardrop-shaped cells with processes, adherent, grow mostly in clumps

STR Profile: May be obtained at <https://strdb.cccells.org/>

Notes: The Childhood Cancer Repository has a matching direct-to-culture diagnosis cell line available from this same patient – CHLA-10

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis.



CHILDREN'S
ONCOLOGY
GROUP



Cell Line Data Sheet for CHLA-9

References:

1. Batra S, Reynolds CP, Maurer BJ. Fenretinide cytotoxicity for Ewing's sarcoma (ES) and primitive neuroectodermal Tumor (PNET) cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. *Cancer Research* 64: 5415-5424, 2004. PubMed ID: 15289350
<https://cancerres.aacrjournals.org/content/64/15/5415.long>
2. Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. *Pediatr Blood Cancer* 56: 239-249, 2011. PubMed ID: 20922763
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005554/>

SEE NCI Pediatric Preclinical Testing Program references.



Cell Line Data Sheet for CHLA-9

Cell Line Name: CHLA-9

Low confluency (10x magnification)

High confluency (10x magnification)

Low confluency (20x magnification)

High confluency (20x magnification)